Cargando…

Resveratrol in Hepatitis C Patients Treated with Pegylated-Interferon-α-2b and Ribavirin Reduces Sleep Disturbance

Background: Hepatitis C virus infection and interferon treatment have shown to be risk factors for sleep disorder health-related quality of life. Aim: To determine whether the effects of resveratrol on sleep disorders were associated with different tests in subjects with chronic hepatitis C treated...

Descripción completa

Detalles Bibliográficos
Autores principales: Pennisi, Manuela, Bertino, Gaetano, Gagliano, Caterina, Malaguarnera, Michele, Bella, Rita, Borzì, Antonio Maria, Madeddu, Roberto, Drago, Filippo, Malaguarnera, Giulia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5579690/
https://www.ncbi.nlm.nih.gov/pubmed/28820468
http://dx.doi.org/10.3390/nu9080897
_version_ 1783260760377393152
author Pennisi, Manuela
Bertino, Gaetano
Gagliano, Caterina
Malaguarnera, Michele
Bella, Rita
Borzì, Antonio Maria
Madeddu, Roberto
Drago, Filippo
Malaguarnera, Giulia
author_facet Pennisi, Manuela
Bertino, Gaetano
Gagliano, Caterina
Malaguarnera, Michele
Bella, Rita
Borzì, Antonio Maria
Madeddu, Roberto
Drago, Filippo
Malaguarnera, Giulia
author_sort Pennisi, Manuela
collection PubMed
description Background: Hepatitis C virus infection and interferon treatment have shown to be risk factors for sleep disorder health-related quality of life. Aim: To determine whether the effects of resveratrol on sleep disorders were associated with different tests in subjects with chronic hepatitis C treated with Peg-IFN-α and RBV. Patients and Methods: In this prospective, randomized, placebo controlled, double blind clinical trial, 30 subjects (Group A) with chronic hepatitis received Pegylated-Interferon-α2b (1.5 mg/kg per week), Ribavirin and placebo (N-acetylcysteine 600 mg and lactoferrin 23.6 g), while 30 subjects (Group B) received the same dosage of Pegylated-Interferon-α2b, Ribavirin and association of N-acetylcysteine 600 mg, lactoferrin 23.6 g and Resveratrol 19.8 mg for 12 months. All subjects underwent laboratory exams and questionnaires to evaluate mood and sleep disorders (General Health Questionnaire (GHQ), Profile of Mood States (POMS), Pittsburgh Sleep Quality Inventory (PSQI), Epworth Sleepiness Scale (ESS)). Results: The comparison between Group A and Group B showed significant differences after six months in C-reactive protein (p < 0.0001); after 12 months in aspartate aminotransferase (AST) (p < 0.0001) Viremia (p < 0.0001), HAI (p < 0.0012) and C-reactive protein (p < 0.0001); and at follow up in AST (p < 0.0001), Viremia (p < 0.0026) and C-reactive protein (p < 0.0001). Significant differences were observed after 12 month and follow-up in General Health Questionnaire, after 1, 6, 12 and follow-up in Profile of Mood States, after 6, 12, follow-up in Pittsburgh Sleep Quality Inventory and Epworth Sleepiness Scale. Conclusions: Supplementation with Resveratrol decreased General Health Questionnaire score and reduced sleep disorders in patients treated with Peg–IFN-α and RBV.
format Online
Article
Text
id pubmed-5579690
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-55796902017-09-06 Resveratrol in Hepatitis C Patients Treated with Pegylated-Interferon-α-2b and Ribavirin Reduces Sleep Disturbance Pennisi, Manuela Bertino, Gaetano Gagliano, Caterina Malaguarnera, Michele Bella, Rita Borzì, Antonio Maria Madeddu, Roberto Drago, Filippo Malaguarnera, Giulia Nutrients Article Background: Hepatitis C virus infection and interferon treatment have shown to be risk factors for sleep disorder health-related quality of life. Aim: To determine whether the effects of resveratrol on sleep disorders were associated with different tests in subjects with chronic hepatitis C treated with Peg-IFN-α and RBV. Patients and Methods: In this prospective, randomized, placebo controlled, double blind clinical trial, 30 subjects (Group A) with chronic hepatitis received Pegylated-Interferon-α2b (1.5 mg/kg per week), Ribavirin and placebo (N-acetylcysteine 600 mg and lactoferrin 23.6 g), while 30 subjects (Group B) received the same dosage of Pegylated-Interferon-α2b, Ribavirin and association of N-acetylcysteine 600 mg, lactoferrin 23.6 g and Resveratrol 19.8 mg for 12 months. All subjects underwent laboratory exams and questionnaires to evaluate mood and sleep disorders (General Health Questionnaire (GHQ), Profile of Mood States (POMS), Pittsburgh Sleep Quality Inventory (PSQI), Epworth Sleepiness Scale (ESS)). Results: The comparison between Group A and Group B showed significant differences after six months in C-reactive protein (p < 0.0001); after 12 months in aspartate aminotransferase (AST) (p < 0.0001) Viremia (p < 0.0001), HAI (p < 0.0012) and C-reactive protein (p < 0.0001); and at follow up in AST (p < 0.0001), Viremia (p < 0.0026) and C-reactive protein (p < 0.0001). Significant differences were observed after 12 month and follow-up in General Health Questionnaire, after 1, 6, 12 and follow-up in Profile of Mood States, after 6, 12, follow-up in Pittsburgh Sleep Quality Inventory and Epworth Sleepiness Scale. Conclusions: Supplementation with Resveratrol decreased General Health Questionnaire score and reduced sleep disorders in patients treated with Peg–IFN-α and RBV. MDPI 2017-08-18 /pmc/articles/PMC5579690/ /pubmed/28820468 http://dx.doi.org/10.3390/nu9080897 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Pennisi, Manuela
Bertino, Gaetano
Gagliano, Caterina
Malaguarnera, Michele
Bella, Rita
Borzì, Antonio Maria
Madeddu, Roberto
Drago, Filippo
Malaguarnera, Giulia
Resveratrol in Hepatitis C Patients Treated with Pegylated-Interferon-α-2b and Ribavirin Reduces Sleep Disturbance
title Resveratrol in Hepatitis C Patients Treated with Pegylated-Interferon-α-2b and Ribavirin Reduces Sleep Disturbance
title_full Resveratrol in Hepatitis C Patients Treated with Pegylated-Interferon-α-2b and Ribavirin Reduces Sleep Disturbance
title_fullStr Resveratrol in Hepatitis C Patients Treated with Pegylated-Interferon-α-2b and Ribavirin Reduces Sleep Disturbance
title_full_unstemmed Resveratrol in Hepatitis C Patients Treated with Pegylated-Interferon-α-2b and Ribavirin Reduces Sleep Disturbance
title_short Resveratrol in Hepatitis C Patients Treated with Pegylated-Interferon-α-2b and Ribavirin Reduces Sleep Disturbance
title_sort resveratrol in hepatitis c patients treated with pegylated-interferon-α-2b and ribavirin reduces sleep disturbance
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5579690/
https://www.ncbi.nlm.nih.gov/pubmed/28820468
http://dx.doi.org/10.3390/nu9080897
work_keys_str_mv AT pennisimanuela resveratrolinhepatitiscpatientstreatedwithpegylatedinterferona2bandribavirinreducessleepdisturbance
AT bertinogaetano resveratrolinhepatitiscpatientstreatedwithpegylatedinterferona2bandribavirinreducessleepdisturbance
AT gaglianocaterina resveratrolinhepatitiscpatientstreatedwithpegylatedinterferona2bandribavirinreducessleepdisturbance
AT malaguarneramichele resveratrolinhepatitiscpatientstreatedwithpegylatedinterferona2bandribavirinreducessleepdisturbance
AT bellarita resveratrolinhepatitiscpatientstreatedwithpegylatedinterferona2bandribavirinreducessleepdisturbance
AT borziantoniomaria resveratrolinhepatitiscpatientstreatedwithpegylatedinterferona2bandribavirinreducessleepdisturbance
AT madedduroberto resveratrolinhepatitiscpatientstreatedwithpegylatedinterferona2bandribavirinreducessleepdisturbance
AT dragofilippo resveratrolinhepatitiscpatientstreatedwithpegylatedinterferona2bandribavirinreducessleepdisturbance
AT malaguarneragiulia resveratrolinhepatitiscpatientstreatedwithpegylatedinterferona2bandribavirinreducessleepdisturbance